ARS Pharmaceuticals, Inc (SPRY) support and resistance · rev $89.1M
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
This page maps ARS Pharmaceuticals, Inc (SPRY) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
SPRY currently screens at market cap $983.1M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new SPRY 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the SPRY quote page for the session range and the stock page for the full model.
Not investment advice.